From 2 June till 6 June 2023: HIGHLIGHTS FROM ASCO

Your direct line with Chicago

The American Society of Clinical Oncology (ASCO) 2023 brings together leading experts in the different fields of cancer from around the world. And, as usual, they gather together in Chicago, USA. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.

Stay tuned, and get ready for an exciting and informative journey!

With the support of:

Daily highlights

Highlights from ASCO

Dr Claudio Cerchione summarised the educational session on the management of multiple myeloma in special patient populations, such as elderly and patients with renal failure.

See video »

Project in the spotlight

ASH Highlights on Multiple Myeloma

Prof Claudio Cerchione, haematologist at the Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy, was so kind to share his highlights on multiple myeloma from

See video »

Health related QoL data of KarMMa-3

KarMMa-3 constitutes an open-label, phase 3 randomized clinical trial aimed at investigating the efficacy of a single infusion of the BCMA-targeting CAR-T cell product ide-cel in comparison to conventional standard-of-care

See video »

In-depth stories

ASH Highlights on Multiple Myeloma

Prof Claudio Cerchione, haematologist at the Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy, was so kind to share his highlights on multiple myeloma from

See video »

Health related QoL data of KarMMa-3

KarMMa-3 constitutes an open-label, phase 3 randomized clinical trial aimed at investigating the efficacy of a single infusion of the BCMA-targeting CAR-T cell product ide-cel in comparison to conventional standard-of-care

See video »

Poster selection

Results from the Phase 1/2 Atalanta-1 trial

An innovative decentralized and automated PoC manufacturing paradigm was devised to facilitate the expeditious administration of freshly prepared autologous CAR-T therapies within a 7-day timeframe following apheresis in patients diagnosed

See video »

The REST study

Dr Frida Bugge Askeland, associated research doctor and PhD student at the Oslo Myeloma Center in Norway summarised the REST study.
In Norway, the use of VRd (bortezomib, lenalidomide and

See video »

Z1. Researchpark 30, 1731 Zellik, Belgium
Website created by MediMix © 2023 - Privacy Policy